SURLORIAN is a novel small-molecule drug candidate and ryanodine receptor stabilizer, classified as a Rycal, currently under investigation for the treatment of conditions such as RYR1-related myopathy… Read more
SURLORIAN is a novel small-molecule drug candidate and ryanodine receptor stabilizer, classified as a Rycal, currently under investigation for the treatment of conditions such as RYR1-related myopathy and other neuromuscular or cardiac disorders characterized by calcium dysregulation. Pharmaceutical laboratories utilize SURLORIAN reference standards and its associated impurities, such as Surlorian Impurity 1, for rigorous analytical testing and method validation. These critical materials support essential processes like impurity profiling, stability assessment, and the precise identification of degradation products throughout drug development. When highly accurate quantification is required for research or quality control, stable isotope labelled compounds function as reliable internal standards for techniques including mass spectrometry. By employing these materials, researchers and quality control scientists ensure the integrity of their analytical methods and maintain compliance with stringent regulatory standards.